| PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and … JM Wood, G Bold, E Buchdunger, R Cozens, S Ferrari, J Frei, F Hofmann, ... Cancer research 60 (8), 2178-2189, 2000 | 1069 | 2000 |
| Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor … B Morgan, AL Thomas, J Drevs, J Hennig, M Buchert, A Jivan, ... Journal of Clinical Oncology 21 (21), 3955-3964, 2003 | 752 | 2003 |
| Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow … J Drevs, I Hofmann, H Hugenschmidt, C Wittig, H Madjar, M Müller, ... Cancer Research 60 (17), 4819-4824, 2000 | 398 | 2000 |
| Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors J Drevs, P Siegert, M Medinger, K Mross, R Strecker, U Zirrgiebel, ... Journal of Clinical Oncology 25 (21), 3045-3054, 2007 | 351 | 2007 |
| Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with … F Kratz, A Warnecke, K Scheuermann, C Stockmar, J Schwab, P Lazar, ... Journal of medicinal chemistry 45 (25), 5523-5533, 2002 | 345 | 2002 |
| Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in … F Eskens, H Dumez, R Hoekstra, A Perschl, C Brindley, S Böttcher, ... European journal of cancer 39 (7), 917-926, 2003 | 308 | 2003 |
| PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular … J Drevs, R Müller-Driver, C Wittig, S Fuxius, N Esser, H Hugenschmidt, ... Cancer research 62 (14), 4015-4022, 2002 | 278 | 2002 |
| First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors B Schultheis, D Strumberg, A Santel, C Vank, F Gebhardt, O Keil, C Lange, ... Journal of clinical oncology 32 (36), 4141-4148, 2014 | 273 | 2014 |
| A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2 AM Mansour, J Drevs, N Esser, FM Hamada, OA Badary, C Unger, ... Cancer research 63 (14), 4062-4066, 2003 | 269 | 2003 |
| A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy F Kratz, R Müller-Driver, I Hofmann, J Drevs, C Unger Journal of medicinal chemistry 43 (7), 1253-1256, 2000 | 214 | 2000 |
| Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours K Mross, J Drevs, M Müller, M Medinger, D Marmé, J Hennig, B Morgan, ... European Journal of Cancer 41 (9), 1291-1299, 2005 | 212 | 2005 |
| Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584 AL Thomas, B Morgan, J Drevs, C Unger, B Wiedenmann, U Vanhoefer, ... Seminars in oncology 30 (3), 32-38, 2003 | 176 | 2003 |
| Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors D Strumberg, B Schultheis, U Traugott, C Vank, A Santel, O Keil, K Giese, ... International Journal of Clinical Pharmacologyand Therapeutics 50 (1), 76, 2012 | 169 | 2012 |
| Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study K Mross, B Niemann, U Massing, J Drevs, C Unger, R Bhamra, ... Cancer chemotherapy and pharmacology 54, 514-524, 2004 | 168 | 2004 |
| Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in … J Drevs, U Zirrgiebel, CIM Schmidt-Gersbach, K Mross, M Medinger, ... Annals of oncology 16 (4), 558-565, 2005 | 151 | 2005 |
| Receptor tyrosine kinases: the main targets for new anticancer therapy J Drevs, M Medinger, C Schmidt-Gersbach, R Weber, C Unger Current drug targets 4 (2), 113-121, 2003 | 135 | 2003 |
| Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy J Drevs, J Fakler, S Eisele, M Medinger, G Bing, N Esser, D Marmé, ... Anticancer research 24 (3A), 1759-1764, 2004 | 129 | 2004 |
| Antiangiogenic potency of FK866/K22. 175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. J Drevs, R Löser, B Rattel, N Esser Anticancer research 23 (6C), 4853-4858, 2003 | 124 | 2003 |
| Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double … MHG Langenberg, CML van Herpen, J De Bono, JHM Schellens, C Unger, ... Journal of Clinical Oncology 27 (36), 6152-6159, 2009 | 119 | 2009 |
| Phase I and pharmacokinetic study of the (6-maleimidocaproyl) hydrazone derivative of doxorubicin C Unger, B Häring, M Medinger, J Drevs, S Steinbild, F Kratz, K Mross Clinical cancer research 13 (16), 4858-4866, 2007 | 117 | 2007 |
